Researchers track hidden infection risk after transplant drug ends

This study aims to understand why some stem cell transplant patients develop a serious viral infection (CMV) after they stop taking a preventive drug. Researchers will observe 123 adult patients who receive the standard preventive drug for 100 days after transplant, tracking their immune system recovery and infection rates for 200 days. The goal is to learn if a patient's immune system strength when stopping the drug predicts their later infection risk, which could help doctors personalize future care.